Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol

E D Bateman, L Fairall, D M Lombardi, R English, E D Bateman, L Fairall, D M Lombardi, R English

Abstract

Background: To compare the efficacy and safety of budesonide/formoterol (Symbicort) with formoterol (Oxis) in the treatment of patients with acute asthma who showed evidence of refractoriness to short-acting beta2-agonist therapy.

Methods: In a 3 hour, randomized, double-blind study, a total of 115 patients with acute asthma (mean FEV1 40% of predicted normal) and a refractory response to salbutamol (mean reversibility 2% of predicted normal after inhalation of 400 microg), were randomized to receive either budesonide/formoterol (320/9 microg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 1280/36 microg]) or formoterol (9 microg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose 36 microg]). The primary efficacy variable was the average FEV1 from the first intake of study medication to the measurement at 90 minutes. Secondary endpoints included changes in FEV1 at other timepoints and change in respiratory rate at 180 minutes. Treatment success, treatment failure and patient assessment of the effectiveness of the study medication were also measured.

Results: FEV1 increased after administration of the study medication in both treatment groups. No statistically significant difference between the treatment groups was apparent for the primary outcome variable, or for any of the other efficacy endpoints. There were no statistically significant between-group differences for treatment success, treatment failure or patient assessment of medication effectiveness. Both treatments were well tolerated.

Conclusion: Budesonide/formoterol and formoterol provided similarly rapid relief of acute bronchoconstriction in patients with asthma who showed evidence of refractoriness to a short-acting beta2-agonist.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Mean increase in FEV1 from baseline in patients treated with either formoterol or budesonide/formoterol. At screening (t = -20 minutes), salbutamol 400 μg was administered to all patients to establish their relative refractoriness to β2-agonist therapy. Patients in the formoterol group received formoterol 9 μg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes (total dose 36 μg). Patients treated with budesonide/formoterol received budesonide/formoterol 320/9 μg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes (total dose 1280/36 μg). The timing of study drug administration is shown by vertical dotted lines on the figure. Patients received oral prednisolone 60 mg 90 minutes after the last administration of study drug.
Figure 3
Figure 3
Change in respiratory rate in patients treated with formoterol or budesonide/formoterol. At screening (t = -20 minutes), salbutamol 400 μg was administered to all patients to establish their relative refractoriness to β2-agonist therapy. Patients in the formoterol group received formoterol 9 μg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes (total dose 36 μg). Patients treated with budesonide/formoterol received budesonide/formoterol 320/9 μg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes (total dose 1280/36 μg). The timing of study drug administration is shown by vertical dotted lines on the figure. Patients received oral prednisolone 60 mg 90 minutes after the last administration of study drug.

References

    1. British Thoracic Society (BTS) British guidelines on the management of asthma. Thorax. 2003;58(Suppl 1):1–94.
    1. Global Initiative for Asthma (GINA) National Institutes of Health [NIH] publication No 02-3659. Bethesda, MD: MIH; 2004. Global Strategy for Asthma Management and Prevention (updated 2004) Accessed on 9 February 2005.
    1. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997;10:2489–2499.
    1. Ringdal N, Derom E, Wahlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler®. Respir Med. 1998;92:1017–1021. doi: 10.1016/S0954-6111(98)90348-1.
    1. Seberová E, Andersson A. Oxis® (formoterol given via Turbuhaler®) showed as rapid an onset of action as salbutamol given by pMDI. Respir Med. 2000;94:607–611. doi: 10.1053/rmed.2000.0788.
    1. Boonsawat W, Charoenratanakul S, Pothirat C, Sawanyawisuth K, Seearamroongruang T, Bengtsson T, Brander R, Selroos O. Formoterol (OXIS®) Turbuhaler® as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med. 2003;97:1067–1074. doi: 10.1016/S0954-6111(03)00139-2.
    1. Rubinfeld A, Scicchitano R, Hunt A, Thompson PJ, Van Nooten A, Hedlund M, Hörstedt AS, Brander R. Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma [Abstract No. P437] Eur Respir J. 2002;20(Suppl 38):41s.
    1. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med. 1994;97:29–37. doi: 10.1016/0002-9343(94)90045-0.
    1. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet. 1995;346:201–206. doi: 10.1016/S0140-6736(95)91265-7.
    1. Aziz I, Lipworth BJ. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and β2-adrenoceptor downregulation after inhaled formoterol. Chest. 1999;115:623–628. doi: 10.1378/chest.115.3.623.
    1. Pansegrouw DF. Acute resistant asthma caused by excessive beta-2-adrenoreceptor agonist inhalation and reversed by inhalation of beclomethasone. S Afr Med J. 1992;82:179–182.
    1. American Thoracic Society (ATS) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987;136:225–244.
    1. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party: standardization of lung function tests. European Community for Steel and Coal. Eur Respir J. 1993;6(Suppl 16):5–40.
    1. Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A, Petermann W, Aubier M, Schwabe G, Bengtsson T, the RELIEF Study investigators Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J. 2003;22:787–794. doi: 10.1183/09031936.03.00055803.
    1. Tattersfield AE, Löfdahl CG, Postma DS, Eivindson A, Schreurs AGM, Rasidakis A, Ekström T. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet. 2001;357:257–261. doi: 10.1016/S0140-6736(00)03611-4.
    1. Balanag VM, Yunus F, Yang P-C, Jorup C. Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents [Abstract No. P2836] Eur Respir J. 2003;22(Suppl 45):445s.
    1. Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med. 1998;157:698–703.
    1. Belleguic C, Corbel M, Germain N, Lena H, Boichot E, Delaval PH, Lagente V. Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients. Clin Exp Allergy. 2002;32:217–223. doi: 10.1046/j.1365-2222.2002.01219.x.
    1. Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. Allergy. 2005;60:23–29. doi: 10.1111/j.1398-9995.2005.00632.x.
    1. Engel T, Dirksen A, Heinig JH, Nielsen NH, Weeke S, Johansson Å. Single-dose inhaled budesonide in subjects with chronic asthma. Allergy. 1991;46:547–553.
    1. FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J, for the Canadian Asthma Exacerbation Study Group Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax. 2004;59:550–556. doi: 10.1136/thx.2003.014936.
    1. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet. 2004;363:271–275. doi: 10.1016/S0140-6736(03)15384-6.
    1. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest. 2000;117:440–446. doi: 10.1378/chest.117.2.440.
    1. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekström T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129–136. doi: 10.1164/rccm.200407-884OC.
    1. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, Boulet L-P, Naya IP, Hultquist C. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20:1403–1418. doi: 10.1185/030079904X2051.
    1. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther. 2003;16:147–151. doi: 10.1016/S1094-5539(03)00004-X.
    1. Rosenborg J, Larsson P, Rott Z, Böcskei C, Poczi M, Juhasz G. Relative therapeutic index between inhaled formoterol and salbutamol in asthmatic patients. Respir Med. 2002;96:412–417. doi: 10.1053/rmed.2002.1291.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi